These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31371418)

  • 1. Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.
    Abrantes JA; Solms A; Garmann D; Nielsen EI; Jönsson S; Karlsson MO
    Haematologica; 2020 May; 105(5):1443-1453. PubMed ID: 31371418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
    Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
    Collins PW; Blanchette VS; Fischer K; Björkman S; Oh M; Fritsch S; Schroth P; Spotts G; Astermark J; Ewenstein B;
    J Thromb Haemost; 2009 Mar; 7(3):413-20. PubMed ID: 19143924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis.
    Bukkems LH; Jönsson S; Cnossen MH; Karlsson MO; Mathôt RAA;
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):706-718. PubMed ID: 36965157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
    Solms A; Iorio A; Ahsman MJ; Vis P; Shah A; Berntorp E; Garmann D
    Clin Pharmacokinet; 2020 May; 59(5):605-616. PubMed ID: 31749076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.
    Tiede A; Abdul Karim F; Jiménez-Yuste V; Klamroth R; Lejniece S; Suzuki T; Groth A; Santagostino E
    Haematologica; 2021 Jul; 106(7):1902-1909. PubMed ID: 32327501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
    Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
    Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A.
    Bukkems LH; Versloot O; Cnossen MH; Jönsson S; Karlsson MO; Mathôt RAA; Fischer K
    Thromb Haemost; 2023 Mar; 123(3):317-325. PubMed ID: 36402130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.
    Abrantes JA; Solms A; Garmann D; Nielsen EI; Jönsson S; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):894-903. PubMed ID: 31668021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.